Trial Profile
A randomised parallel group trial to investigate the effect of Seretide [salmeterol/fluticasone-propionate] withdrawal in COPD [chronic obstructive pulmonary disease] using non-invasive biomarkers and physiological measurements
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Sep 2019
Price :
$35
*
At a glance
- Drugs Salmeterol/fluticasone propionate (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Biomarker; Therapeutic Use
- 07 Apr 2011 Actual end date (31 Jul 2007) added as reported by ISRCTN: Current Controlled Trials.
- 01 Nov 2009 Results published in the European Journal of Clinical Pharmacology.
- 16 May 2008 Secondary endpoint 'pH' has not been met.